

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

**LI et al.**

Atty. Ref.: **2824-9**

Serial No. **09/145,180**

Group: **1617**

Filed: **September 1, 1998**

Examiner: **Wang, S.**

For: **OXO-SUBSTITUTED COMPOUNDS, PROCESS OF  
MAKING, AND COMPOSITIONS AND METHODS FOR  
INHIBITING PARP ACTIVITY**

\* \* \* \* \*

**March 5, 2002**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**SUBMISSION**

Supplemental to the Response filed March 4, 2002, in the above (copy attached) submitted herewith is a paper copy of the previously filed references and Information Disclosure Statement. As explained in the attached Response, the references are being delivered directly to the Examiner to assure receipt of the same by the Examiner. Return of an initialed copy of the PTO-1449 Forms listing the attached references (copy attached), pursuant to MPEP §609, is requested. Moreover, return of an initialed copy of the PTO-1449 Form filed with the Supplemental Information Disclosure Statement filed November 9, 2001, pursuant to MPEP §609, is requested.


**RECEIVED**  
MAR 06 2002  
TECH CENTER 1600/2900  
RECEIVED  
TECH CENTER 1600/2900  
MAR -5 AM 10:17

LI et al.  
Serial No. 09/145,180

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_



**B. J. Sadoff**  
Reg. No. 36,663

**BJS:eaw**  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

In re Patent Application of

Atty Dkt. 2824-9

Li et al.

C# M#

Group Art Unit: 1617

Serial No. 09/145,180

Examiner: Wang, S.

Filed: September 1, 1998

Date: March 4, 2002

Title: OXO-SUBSTITUTED COMPOUNDS, PROCESS OF MAKING, AND  
COMPOSITIONS AND METHODS FOR INHIBITING PARP ACTIVITYAssistant Commissioner for Patents  
Washington, DC 20231

COPY

RECEIVED  
TECH CENTER 1000/2800  
MAR -5 AM 10:18

Sir:

**RESPONSE/AMENDMENT/LETTER**

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

**Fees are attached as calculated below:**

Total effective claims after amendment	0	minus highest number		
previously paid for	20	(at least 20) =	0 x	\$ 18.00
				\$ 0.00

Independent claims after amendment	0	minus highest number		
previously paid for	3	(at least 3) =	0 x	\$ 34.00
				\$ 0.00

If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper)	\$ 0.00
--	---------

Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months)	\$ 0.00
--	---------

Terminal disclaimer enclosed, add \$ 110.00	\$ 0.00
---	---------

<input type="checkbox"/> First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00)	\$ 0.00
---	---------

<input type="checkbox"/> Please enter the previously unentered, filed	
---	--

<input type="checkbox"/> Submission attached	
--	--

<b>Subtotal</b>	<b>\$ 0.00</b>
-----------------	----------------

If "small entity," then enter half (1/2) of subtotal and subtract	-\$ 0.00
---	----------

<input type="checkbox"/> Applicant claims "small entity" status.	<input type="checkbox"/> Statement filed herewith
--	---

Rule 56 Information Disclosure Statement Filing Fee (\$180.00)	\$ 0.00
--	---------

Assignment Recording Fee (\$40.00)	\$ 0.00
------------------------------------	---------

Other:	0.00
--------	------


<b>TOTAL FEE ENCLOSED</b>	<b>\$ 0.00</b>
---------------------------	----------------

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8<sup>th</sup> Floor  
Arlington, Virginia 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100  
BJS:eaw

NIXON & VANDERHYE P.C.  
By Atty: B. J. Sadoff, Reg. No. 36.663

Signature: \_\_\_\_\_



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

LI et al.

Atty. Ref.: 2824-9

Serial No. 09/145,180

Group: 1617

Filed: September 1, 1998

Examiner: Wang, S.

For: OXO-SUBSTITUTED COMPOUNDS, PROCESS OF  
MAKING, AND COMPOSITIONS AND METHODS FOR  
INHIBITING PARP ACTIVITY  
\* \* \* \* \*

March 4, 2002

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**RESPONSE**

Responsive to the Official Action dated December 4, 2001, entry and consideration of the following remarks are requested.

A paper copy of the previously cited references will be hand carried to the Examiner, with a copy of this Response on March 5, 2002. The references are not being attached herewith as the paper copy of the references fills two boxes and the undersigned believes the references would more directly be received by the Examiner if hand-carried to the Group. The Examiner is requested to contact the undersigned in the event the references are not included with the file when the Examiner next reaches the case for Action. A copy of the previously filed Information Disclosure Statement is attached hereto and return of an initialed copy of the PTO-1449 Forms, pursuant to MPEP §609, is requested. The Examiner is requested to contact the undersigned if anything further is required in this regard.

RECEIVED  
MAR 5 2002  
AM 10:18  
FBI CENTER


Claims 184-233 are pending. Claims 193-195, 197-206, 208, 214, 215 and 217-233 have been withdrawn from consideration.

The Section 103 rejection of claims 184-192, 196, 207, 209, 213 and 216 over Weltin in view of Banasik, Suto and Endres, is traversed. Reconsideration and withdrawal of the rejection are requested in view of the following further distinguishing comments.

The Examiner's additional citation of Banasik fails to cure the deficiencies of Weltin, Suto and Enders, previously detailed on pages 6-9 of the Amendment dated June 29, 2001, which the Examiner is requested to review.


Moreover, the applicants submit that the Examiner has impermissibly selected elements from Endres, Suto, Banasik and Weltin in an attempt to reconstruct the presently claimed invention, in hindsight. The Examiner has, in the applicants' view, used the presently claimed invention as a "road map" to impermissibly piece together the prior art in an attempt to make the presently claimed invention. Moreover, the applicants submit there is no suggestion or motivation to combine these four references, in the art, absent the applicants' teaching.

Specifically, the applicants state that Weltin discusses three completely different compounds that show PARP activity, i.e., 1, 5-dihydroxyisoquinoline which has the following structure:




1,5-dihydroxyisoquinoline

6(5H)-phenanthridinone, which has the following structure:



6(5H)-phenanthridinone

and 3-methoxybenzamide, which has the following structure:




3-methoxybenzamide

The Examiner will appreciate that only one of these noted structures from Weltin is a phenanthridinone. The Examiner is requested to consider the reference as a whole, as opposed to selecting particular aspects of the claimed invention, as may suit the Examiner's arguments.


The Examiner concludes, on page 3, third full paragraph, of the Office Action dated December 4, 2001 (Paper No. 23), that it would have allegedly been obvious to a

person of ordinary skill in the art to employ substituted 6(5H)-phenanthrindinone, e.g., 10-amino-2-nitro-6(5H)-phenanthrindinone for treating ischemia. The applicants submit however that the references teach, at best, that it may have been obvious to try to treat ischemia with such a compound however one of ordinary skill in the art was not taught by the cited references, nor is there a suggestion in the cited art, to carry out such a method. The Examiner's rationale is not sufficient to rise to the level of establishing a *prima facie* case of obviousness and accordingly, the Section 103 rejection should be withdrawn.


The Examiner asserts that "a derivative of 6(5H)-phenanthrindinone is reasonably expected to be similar useful [sic]" allegedly in light of the fact that 10-amino-2-nitro-6(5H)-phenanthrindinone was taught by Banasik to be a PARP inhibitor. See, page 3, last paragraph, of Paper No. 23. The applicants submit however that Weltin describes three PARP inhibitors with three completely different compounds containing different functional groups, as follows:



Moreover, Banasik shows PARP activity among 76 different compounds, only two of which are phenanthrindinones. Suto discloses that substituted isoquinolines of the following structure:



would have a wide range of activity, some of which are essentially inactive (i.e.,  $IC_{50}=120$ ). Finally, Endres only relates to the use of 3-aminobenzamide which has the following structure:



The Examiner's combination of references would, at best, only provide a invitation to further experimentation, rather than making the presently claimed invention obvious. There is no motivation in the cited references to combine the same and the Examiner has combined the references through an inappropriate use of hindsight. The Examiner's response to the applicants' previous comments, are noted. The Examiner appears to believe that phenanthridinone is a derivative of isoquinolinones because phenanthridinones contain the isoquinolinone moiety. The Examiner's reasoning however would make any compound that contained an isoquinolinone moiety a derivative and the teachings of the cited art applicable thereto. The cited art however is not as broad as the Examiner's application of the same. Withdrawal of the Section 103 rejection is requested.




LI et al.  
Serial No. 09/145,180

In view of the above, the claims are submitted to be in condition for allowance and a Notice to that effect is requested. The Examiner is requested to contact the undersigned if anything further is required in this regard.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_



**B. J. Sadoff**  
Reg. No. 36,663

**BJS:eaw**  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Copy  
# 22

In re Patent Application of

LI et al.

Atty. Ref.: 2824-9

Serial No. 09/145,180

Group: 1617

Filed: September 1, 1998

Examiner: Wang, S.

For: OXO-SUBSTITUTED COMPOUNDS, PROCESS OF MAKING,  
AND COMPOSITIONS AND METHODS FOR INHIBITING  
PARP ACTIVITY

\* \* \* \* \*

August 30, 2001

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**INFORMATION DISCLOSURE STATEMENT**

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited

by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

The attached PTO-1449 forms indicate the document number ("Doc No.") relating to each listed document. Documents which have been previously considered are indicated as "Duplicate" in the "Examiner's Initials" column. A copy of each of the listed documents is attached. Documents numbered through number 549 are attached on the attached CD disk and may be accessed, reviewed, and printed, if needed, as described below. A paper copy of documents 550-568 is attached.

The documents on the CD disk may be accessed, reviewed, and printed, if need be, as follows. After placing the CD in the CD drive, review the contents of the disk such as, for example, by use of Windows Explorer. Load the program "Cdview.exe" by, for example, double left - clicking on the icon for the same in the Explorer Window. This will load a program "Ipro Tech" and present the first document, which is document zero on the disk. The first document (document zero) on the disk is a copy of the index of the numbered documents. Each document on the disk is identified by a nine digit identifier wherein the first three digits identify the document number and the remaining digits identify the page of each document. The index which is first presented can be seen to contain ten pages wherein page 1 is shown. See, the top border of the program screen. The documents may be viewed smaller or larger using the "-" or "+", respectively, in the magnifying glass icons shown along the top of the program screen. Pages of the first document may be viewed in successive order using the greater than symbol, along the bottom border of the program screen, which is second from the left in the series of buttons. The last page of the index (document zero), or any document, may be viewed by clicking on the fourth button from the left along the bottom screen of the program. Successive or previous documents may be viewed by clicking on the directional arrows shown over a picture of a folder, which are the seventh and eighth buttons from the left along the bottom border of the program screen.

Alternatively, documents may be more directly accessed by left clicking on the "File" word along the top border of the program screen and then left clicking on the "Goto Image" words, followed by entry of the nine digit identifier described above in the "Enter Image Key" screen presented. The "Enter" key on the keyboard may be then pressed or the "OK" button left clicked to move to the desired document.

Again, the documents are numbered according to those found in the attached PTO-1449 form with a nine digit code wherein the first three digits identify the document number and the

remaining six digits identify the page number within the document which is requested. For example, document no. (Doc No.) 468 is indicated in the attached PTO-1449 form as being U.S. Patent No. 932,290. This document may be accessed, viewed, and printed, if need be, by left clicking on the "File" and then "Goto Image", as noted above, followed by entry of the number 468000001, for document number 468, page 1. Upon left clicking on "OK" or pressing "Enter" on the keyboard, the image of page 1 of U.S. Patent No. 932,290 appears. Separate pages of the document may be viewed and/or accessed, as described above.

Individual pages may be printed or entire documents may be printed by left clicking on the printer icon along the top of the viewer and clicking on the "Current Page Only", "Entire Document", or other desired option.

The Examiner is requested to contact the undersigned if questions arise or if anything further is required.

Applicants have checked the appropriate boxes below.

1. ☒ This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No statement under 37 C.F.R. § 1.97(e) or fee is required. In the event, a first Office Action has been mailed prior to filing of the present Information Disclosure Statement, the Office is requested to treat the present paper as submission under 37 C.F.R. § 1.97(c) and charge the undersigned's Deposit Account No. 14-1140 for the fee required by 37 C.F.R. § 1.17(p). The present paper is submitted in duplicate for this purpose.

2. ☐ This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.

- a. ☐ I hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
- b. ☐ I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more

than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).

- c. ☐ Attached is our Check in the amount of \$180 in payment of the fee under 37 C.F.R. § 1.17(p).

3. ☐ This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. It is hereby requested that the Information Disclosure Statement be considered. Attached is our Check No. in the amount of \$ in payment of the fee under 37 C.F.R. § 1.17(i).

- a. ☐ I hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
- b. ☐ I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).

4. ☐ Relevance of the non-English language document(s) is discussed in the present specification.

5. ☒ Some of the document(s) was/were cited in a corresponding foreign application. An English language version of the foreign search reports is attached for the Examiner's information.

6. ☐ A concise explanation of the relevance of the non-English language document(s) appears below:

7. ☒ The Examiner's attention is directed to co-pending U.S. Patent Application Nos. listed in the following table, (copies attached as the noted document numbers) which are directed to related technical subject matter. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to these applications now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application

and the art cited therein during examination and return an initialed copy of the following Table as an indication of the same.

Examiner's Initials	Doc. No.	U.S. Application No.	Year	Applicant	Status
	80	08/922,520	1997	Jackson et al.	abandoned
	96	08/922,575	1997	Jackson et al.	abandoned
	97	08/922,548	1997	Jackson et al.	pending
	549	09/387,767	1999	Li et al.	allowed
	1	09/224,294	1999	Zhang et al.	U.S. Patent No. 6201020
	7	09/224,293	1998	Zhang et al.	pending
	16	09/145,180	1998	Li et al.	pending
	17	09/145,184	1998	Li et al.	pending
	18	09/145,185	1998	Li et al.	U.S. Patent No. 6121273
	19	09/079,514	1998	Li et al.	abandoned
	20	09/079,510	1998	Li et al.	abandoned
	21	09/079,509	1998	Li et al.	abandoned
	22	09/047,302	1998	Li et al.	allowed
	27	09/145,179	1998	Jackson et al.	pending
	28	09/145,178	1998	Jackson et al.	pending
	29	09/145,177	1998	Jackson et al.	abandoned
	30	09/145,176	1998	Jackson et al.	pending
	31	09/145,166	1998	Jackson et al.	U.S. Patent No. 6197785
	32	09/079,513	1998	Jackson et al.	abandoned
	33	09/079,512	1998	Jackson et al.	abandoned
	33	09/689,942	1998	Jackson et al.	pending
	34	09/079,511	1998	Jackson et al.	abandoned
	35	09/079,508	1998	Jackson et al.	pending
	36	09/079,507	1998	Jackson et al.	abandoned

Examiner: \_\_\_\_\_ Date Considered: \_\_\_\_\_

8. ☐ Copies of the documents were cited by or submitted to the Office in Application No. , filed , which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 14-1140 referencing docket number 2824-9 for any fee required for consideration of the attached.


Return of an initialed copy of the attached, pursuant to MPEP § 609, is requested.

LI et al.  
Serial No. 09/145.180

Respectfully submitted.

NIXON & VANDERHYE P.C.

By:



B. J. Sadoff

Reg. No. 36,663

BJS:eaw  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

# INFORMATION DISCLOSURE STATEMENT - FORM PTO 1449

Attorney Docket No. 282

Serial No. 09/145,180

Applicant: LI et al.

Filing date: September 1, 1998

Group 1617

Page 1 of 13 of PTO 1449

Examiner's Initials	Doc. No.	Journal name or type of document	Journal vol., no., page or Patent No.	Mo./Year	Author/Patentee	Class	Subclass	Filing date if appropriate
<i>SW</i>		U.S. Patents						
<i>SW</i>	468	U.S. Patent	932,290	8/1909	Kacer et al.			
<i>SW</i>	467	U.S. Patent	1,001,325	8/1911	Ullman et al.			
<i>SW</i>	464	U.S. Patent	1,253,252	1/1918	Karcos et al.			
Duplicate	462	U.S. Patent	1,350,441	10/1922	Meidenreich et al.			
Duplicate	461	U.S. Patent	1,395,105	1/1933	Rath et al.			
Duplicate	459	U.S. Patent	2,467,692	4/1949	Petrow et al.			
	454	U.S. Patent	2,612,503	9/1952	Uillyot			
	455	U.S. Patent	2,593,798	4/1952	Robinson			
	453	U.S. Patent	2,638,472	5/1953	Grewé			
	452	U.S. Patent	2,666,059	1/1954	Davis et al.			
	450	U.S. Patent	2,700,040	1/1955	Uillyot			
	432	U.S. Patent	2,392,841	6/1959	Rudner			
	426	U.S. Patent	2,992,220	7/1961	Irving et al.			
Duplicate	398	U.S. Patent	3,291,801	12/1966	Montgomery			
	400	U.S. Patent	3,247,212	4/1966	Johnson			
Duplicate	394	U.S. Patent	3,300,499	1/1967	Lesner et al.			
	388	U.S. Patent	3,403,157	9/1968	Humber et al.			
	379	U.S. Patent	3,534,038	10/1970	Macnatzke et al.			
	380	U.S. Patent	3,507,872	4/1970	Hegar			
Duplicate	372	U.S. Patent	3,557,119	1/1971	Humber et al.			
Duplicate	373	U.S. Patent	3,573,304	3/1971	Eberle et al.			
Duplicate	361	U.S. Patent	3,700,673	10/1972	Watson, Jr.			
	352	U.S. Patent	3,719,564	3/1973	Unger et al.			
	357	U.S. Patent	3,759,924	9/1973	Jeanmart et al.			
	346	U.S. Patent	3,838,134	9/1974	Gauthier			
	347	U.S. Patent	3,330,816	8/1974	Gittos et al.			
	338	U.S. Patent	3,399,529	8/1975	Witzel			
Duplicate	340	U.S. Patent	3,900,477	8/1975	Philipp et al.			
Duplicate	327	U.S. Patent	3,978,066	8/1976	Philipp et al.			
Duplicate	328	U.S. Patent	3,950,343	4/1976	Philipp et al.			
Duplicate	332	U.S. Patent	3,932,643	1/1976	Gauthier			
Duplicate	335	U.S. Patent	3,991,064	11/1976	Brown et al.			
Duplicate	322	U.S. Patent	4,031,097	6/1977	Bach et al.			
	310	U.S. Patent	4,082,741	4/1978	Hunger et al.			
	303	U.S. Patent	4,169,897	10/1979	Meyer et al.			
	297	U.S. Patent	4,218,453	8/1980	Hannan			
	281	U.S. Patent	4,309,543	1/1982	Keeley			
	273	U.S. Patent	4,382,943	5/1983	Winter et al.			
Duplicate	270	U.S. Patent	4,472,401	9/1984	Kennewell et al.			
Duplicate	272	U.S. Patent	Re. 31,617	6/1984	Beverung, Jr. et al.			
<i>SW</i>	253	U.S. Patent	4,594,415	6/1986	Robins et al.			
<i>SW</i>	245	U.S. Patent	4,639,454	1/1987	Hesson			

Examiner: *SW* Date Considered: 5-22-02

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modeled after Form PTO 1449



INFORMATION DISCLOSURE STATEMENT - FORM PTO 1449

Attorney Docket No. 2824

Serial No. 09/145,180

Applicant: LI et al.

Filing date: September 1, 1998

Group 1617

Page 2 of 13 of PTO 1449

Examiner's Initials	Doc No.	Journal name or type of document	Journal vol., no., page or Patent No.	Mo./Year	Author/Patentee	Class	Subclass	Filing date if appropriate
<i>SV</i>	233	U.S. Patent	4,740,581	3/1988	Pruett et al.			
Duplicate	235	U.S. Patent	4,742,171	5/1988	Martin et al.			
<i>SV</i>	219	U.S. Patent	4,925,368	5/1990	Sestanj et al.			
Duplicate	220	U.S. Patent	4,902,695	2/1990	Ornstein			
<i>SV</i>	221	U.S. Patent	4,952,798	2/1990	Nakamitsu et al.			
<i>SV</i>	198	U.S. Patent	5,077,035	12/1991	Wieland et al.			
Duplicate	207	U.S. Patent	5,041,553	8/1991	Lee et al.			
<i>SV</i>	208	U.S. Patent	5,032,517	7/1991	Lee et al.			
Duplicate	171	U.S. Patent	5,177,075	1/1993	Suto et al.			
<i>SV</i>	175	U.S. Patent	5,274,097	12/1993	Schone et al.			
<i>SV</i>	176	U.S. Patent	5,262,564	11/1993	Schone et al.			
<i>SV</i>	178	U.S. Patent	5,215,738	6/1993	Lee et al.			
<i>SV</i>	179	U.S. Patent	5,262,564	11/1993	Kun et al.			
Duplicate	163	U.S. Patent	5,338,851	8/1994	Huff et al.			
Duplicate	133	U.S. Patent	5,420,136	5/1995	Lewis et al.			
<i>SV</i>	135	U.S. Patent	5,473,074	12/1995	Kun et al.			
<i>SV</i>	136	U.S. Patent	5,464,871	11/1995	Kun et al.			
Duplicate	139	U.S. Patent	5,414,001	3/1995	Ireland et al.			
<i>SV</i>	145	U.S. Patent	5,395,835	3/1995	Glase et al.			
<i>SV</i>	149	U.S. Patent	5,434,188	7/1995	Boschnelli et al.			
<i>SV</i>	477	U.S. Patent	5,391,376	2/1995	Long, Jr. et al.			
Duplicate	99	U.S. Patent	5,537,384	12/1996	Zhang et al.			
Duplicate	102	U.S. Patent	5,569,483	12/1996	West			
<i>SV</i>	114	U.S. Patent	5,516,941	5/1996	Kun et al.			
	115	U.S. Patent	5,482,975	1/1996	Kun et al.			
	476	U.S. Patent	5,480,631	1/1996	De Paulis et al.			
	70	U.S. Patent	5,665,710	9/1997	Ranman et al.			
	76	U.S. Patent	5,670,518	9/1997	Kun et al.			
	77	U.S. Patent	5,652,367	7/1997	Kun et al.			
	78	U.S. Patent	5,652,260	7/1997	Kun et al.			
	82	U.S. Patent	5,703,116	12/1997	Gaeta et al.			
	83	U.S. Patent	5,656,638	8/1997	Gaeta et al.			
	84	U.S. Patent	5,659,082	8/1997	Flitter et al.			
<i>SV</i>	90	U.S. Patent	5,633,282	5/1997	Collins et al.			
Duplicate	91	U.S. Patent	5,618,813	4/1997	Chu et al.			
<i>SV</i>	92	U.S. Patent	5,703,089	12/1997	Braña et al.			
<i>SV</i>	95	U.S. Patent	5,635,506	6/1997	Albers et al.			
<i>SV</i>	13	U.S. Patent	5,719,151	2/1998	Shall et al.			
<i>SV</i>	23	U.S. Patent	5,753,674	5/1998	Kun et al.			
Duplicate	38	U.S. Patent	5,756,510	5/1998	Griffin et al.			
<i>SV</i>	39	U.S. Patent	5,760,062	6/1998	Gaeta et al.			
Duplicate	40	U.S. Patent	5,767,135	6/1998	Fernandez-Poi			
<i>SV</i>	501	US patent	3,904,671	9/1975	Minatoya			
<i>SV</i>	548	US patent	RE 36,397	11/1999	Zhang et al.			

Examiner: *SV* <sup>2</sup> Date Considered: *5/22/02*

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modeled after Form PTO 1449

# INFORMATION DISCLOSURE STATEMENT - FORM PTO 1449

Attorney Docket No. 2824-9

Serial No. 09/145,180

Applicant: LI et al.

Filing date: September 1, 1998

Group 1617

Page 3 of 13 of PTO 1449

Examiner's Initials	Doc No.	Journal name or type of document	Journal vol., no., page or Patent No.	Mo./Year	Author/Patentee	Class	Success	Filing date if appropriate
SW	549	U.S. Patent	6,121,272	9/2000	Li et al.			
	550	U.S. Patent	6,121,273	9/2000	Jackson et al.			
	558	U.S. Patent	6,201,020	3/2001	Zhang			
	559	U.S. Patent	6,235,748	3/2001	Li et al.			
	560	U.S. Patent	6,197,745	3/2001	Jackson et al.			
	566	U.S. Patent	3,723,436	3/1973	Huilestein et al.			
		FOREIGN PATENT DOCUMENTS						
	431	Belgium	562948	1960				
	421	Belgium	628255	1963				
	331	Canada	1000701	1976	Humber et al.			
	246	Canada	1,278,141	1987	Domo et al.			
	247	Canada	1,274,339	1987	Domo et al.			
	515	CH patent	CH-463 779	1965	Hofer et al.			
	516	DE patent	DE-A-2111910	1971	Redies et al.			
	514	DE patent	DE-A-2429515	1973	Refies et al.			
	495	EP patent	393925	1990	Brown et al.			
	500	EP patent	EP 0675 201	1995	Medlen et al.			
	305	EPO	0 005 232 A	1979	Hoechst AG			
	271	EPO	0 126 684 B1	1984	Haslam et al.			
	255	EPO	0 197 716 B1	1986	Della Valle et al.			
	256	EPO	0 212 959 B1	1986	Bawa et al.			
	257	EPO	0 219 208 B1	1986	Sawa			
	217	EPO	355 750	1990	Suto et al.			
	218	EPO	0 393 926	1990	SmithKline			
	227	EPO	0 555 750	1990				
	197	EPO	0 539 805	1992				
SW	165	EPO	0 638 309 A1	1994	Gorio et al.			
SW	446	France	1 199 252	1957				
SW	382	France	FR 7 723 M	1970				
Duplicate	351	France	2 205 333	1974				
SW	326	France	2 305 182	1976	Troxier et al.			
	465	German Patent	282711	1915	Kardos et al.			
	466	German Patent	D.R.P. 282711	1915				
	445	German Patent	963 184	1957				
	311	German Patent	DE 26 50 226	1978	Henkel Kgaa			
	263	German Patent	DE 33 32 633 A	1985				
	434	Great Britain Patent	810,108	1959				
	429	Great Britain Patent	838,994	1960	Irving et al.			
	368	Great Britain Patent	1,263,044	1972				
	342	Great Britain Patent	1,379,111	1975	Gittos			
	317	Great Britain Patent	1,474,775	1977	Troxier et al.			
	301	Great Britain Patent	1,545,767	1979	Simmonds			
SW	469	Japanese patent	4-275296	1992				
	470	Japanese patent	4-275223	1992				

Examiner: SW 3 Date Considered: 5/22/07

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not copy of this form with next communication to applicant.

Modeled after Form PTO 1449

542363

INFORMATION DISCLOSURE STATEMENT - FORM PTO 1449

Attorney Docket No. 2824-9

Serial No. 09/145,180

Applicant: LI et al.

Filing date: September 1, 1998

Group 1617

Page 4 of 13 of PTO 1449

Examiner's Initials	Doc No.	Journal name or type of document	Journal vol., no., page or Patent No.	Mo./Year	Author/Patentee	Class	Subclass	Filing date if appropriate
<i>SW</i>	471	Japanese Patent	4-13684	1992				
<i>SW</i>	472	Japanese patent	3-205402	1991				
<i>SW</i>	201	Japanese Patent	032 05402 A2	1991	Tanuma			
<i>SW</i>	214	Japanese Patent	042 75226 A2	1991				
<i>SW</i>	191	Japanese Patent	040 17684 A2	1992	Tanuma			
<i>SW</i>	196	Japanese Patent	042 75223 A2	1992				
	499	PCT	WO 99/11645	1999				
	504	PCT	WO 00/39070	2000	Zhang et al.			
	505	PCT	WO 00/39104	2000	Zhang et al.			
	215	PCT	WO 90/07502	1990	Vecchiotti et al.			
	192	PCT	WO 92/15286	1992	Shikani			
	193	PCT	WO 92/05770	1992	Meadows			
	195	PCT	WO 92/00281	1992	Alberts et al.			
	177	PCT	WO 93/18748	1993	Meadows			
	183	PCT	WO 93/05096	1993	Domb et al.			
<i>SW</i>	124	PCT	WO 95/30409	1995	Winters et al.			
Duplicate	141	PCT	WO 95/24379	1995	Griffin et al.			
<i>SW</i>	146	PCT	WO 95/29895	1995	Fernandez et al.			
	151	PCT	WO 95/04720	1995				
	112	PCT	WO 96/33268	1996	Miller et al.			
	497	PCT	WO 96/28167	1996	Shaskan			
	66	PCT	WO 97/30054	1997	Reddy et al.			
	94	PCT	WO 97/38977	1997	Astra Pharmaceutical			
	9	PCT	WO 98/27975	1998	West			
	2	PCT	WO 99/11624	1999	Li et al.			
	3	PCT	WO 99/11649	1999	Jackson et al.			
	4	PCT	WO 99/11644	1999	Jackson et al.			
	506	PCT	WO 99/11623	1999	Jackson et al.			
	507	PCT	WO 99/11628	1999	Jackson et al.			
	508	PCT	WO 99/11622	1999	Jackson et al.			
	509	PCT	WO 99/59975	1999	Li et al.			
	510	PCT	WO 99/11644	1999	Jackson et al.			
	511	PCT	WO 99/11645	1999	Li et al.			
	512	PCT	WO 99/11649	1999	Jackson et al.			
	513	PCT	WO 99/59973	1999	Li et al.			
	565	PCT (2824-120) PCT/US00/023745	WO 01/16137	2001	Li et al.			
	545	WO for PCT/US99/30971	PCT/US99/30971	2000				
		OTHER DOCUMENTS						
	172	Abstr Pap Am Chem Soc	206 (2)	1993	Slama et al.			
	154	Abstract	1994:425593	1994	Zailsev et al.			
	474	Aldrich	Catalog #23,559-3					
	416	Angew. Chem.	76:1, 50	1964	Baer et al.			
<i>SW</i>	411	Ann.	673:132-36	1964	Reid et al.			

Examiner: *S. V. W. O* <sup>4</sup> Date Considered: *5/22/02*

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modeled after Form PTO 1449

## INFORMATION DISCLOSURE STATEMENT - FORM PTO 1449

Attorney Docket No. 2824

Serial No. 09/145,180

Applicant: LI et al.

Filing date: September 1, 1998

Group 1617

Page 5 of 13 of PTO 1449

Examiner's Initials	Doc No.	Journal name or type of document	Journal vol., no., page or Patent No.	Mo./Year	Author/Patentee	Class	Subclass	Filing date if appropriate
SW	404	Ann. Chem.	688:177-88	1965	Feld et al.			
Duplicate	89	Ann. N.Y. Acad. Sci.	825:366-79	1997	Cosi et al.			
SW	225	Annu. Rev. Neurosci.	13: 171-82	1990	Choi et al.			
Duplicate	202	Anticancer Drug Des.	7:107-17	1991	Suto et al.			
Duplicate	143	Anticancer Drug Design	10(5):507-14 (Sept)	1995	Griffin et al.			
SW	131	Anti-Cancer Drug Design	10(5): 507-14	1995	R. Grinin et al.			
SW	203	Anticancer Research	11: 381-888	1991	Sakagami et al.			
SW	393	Arch. Pharm. Ber. Dtsch. Pharm. Ges.	300:5, 533-39	1967	Reisch			
Duplicate	457	Beilstein Handbook of Organic Chem.	Reg. No. 158523	1950				
Duplicate	449	Beilstein Handbook of Organic Chem.	Reg. No. 233692	1956				
SW	517	Beilstein Handbook of Organic Chem.	Reg. No. 618403	1988	Dokunichin			
	518	Beilstein Handbook of Organic Chem.	Reg. No. 827161	1988	Dokunichin			
	519	Beilstein Handbook of Organic Chem.	Reg. No. 821484	1988	Dokunichin			
	520	Beilstein Handbook of Organic Chem.	Reg. No. 619108	1988	Dokunichin			
	521	Beilstein Handbook of Organic Chem.	Reg. No. 657772	1988	Dokunichin			
	522	Beilstein Handbook of Organic Chem.	Reg. No. 653888	1988	Dokunichin			
	525	Beilstein Handbook of Organic Chem.	Reg. No. 307993	1988	Sieilitz			
	526	Beilstein Handbook of Organic Chem.	Reg. No. 746893	1988	Dokunichin			
	527	Beilstein Handbook of Organic Chem.	Reg. No. 556117	1988	Gomes			
	528	Beilstein Handbook of Organic Chem.	Reg. No. 1571164	1988	Rokach			
	529	Beilstein Handbook of Organic Chem.	Reg. No. 1541605	1988	Humber et al.			
	530	Beilstein Handbook of Organic Chem.	Reg. No. 751834	1988	Mavoungou Gomes			
	531	Beilstein Handbook of Organic Chem.	Reg. No. 670954	1988	Mavoungou Gomes			
	532	Beilstein Handbook of Organic Chem.	Reg. No. 649696	1988	Dokunichin			
	533	Beilstein Handbook of Organic Chem.	Reg. No. 530731	1988	Dokunichin			
	534	Beilstein Handbook of Organic Chem.	Reg. No. 660681	1988	Dokunichin			
	523	Beilstein Handbook of Organic Chem.	Reg. No. 4483194	1991	Oleinik			
	524	Beilstein Handbook of Organic Chem.	Reg. No. 4494786	1991	Oleinik			
	47	Beilstein Handbook of Organic Chem.	Reg. No. 3140506	1998				
	48	Beilstein Handbook of Organic Chem.	Reg. No. 56052	1998				
	49	Beilstein Handbook of Organic Chem.	Reg. No. 332938	1998				
	50	Beilstein Handbook of Organic Chem.	Reg. No. 254129	1998				
	51	Beilstein Handbook of Organic Chem.	Reg. No. 245245	1998				
	52	Beilstein Handbook of Organic Chem.	Reg. No. 244756	1998				
	53	Beilstein Handbook of Organic Chem.	Reg. No. 222316	1998				
	54	Beilstein Handbook of Organic Chem.	Reg. No. 207532	1998				
	55	Beilstein Handbook of Organic Chem.	Reg. No. 207516	1998				
	56	Beilstein Handbook of Organic Chem.	Reg. No. 165349	1998				
	57	Beilstein Handbook of Organic Chem.	Reg. No. 161148	1998				
	5	Beilstein Handbook of Organic Chem.	Reg. No. 2213597	1999				
SW	6	Beilstein Handbook of Organic Chem.	Reg. No. 13823	1999				
Duplicate	294	Biochem. J.	185: 775-77	1980	Purnell et al.			
SW	251	Biochemical and Biophysical Research	136(3), 1110-15	1986	Tanuma et al.			

Examiner: SW Date Considered: 5/22/02

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modeled after Form PTO 1449

INFORMATION DISCLOSURE STATEMENT - FORM PTO 1449

Attorney Docket No. 2824-

Serial No. 09/145,180

Applicant: LI et al.

Filing date: September 1, 1998

Group 1617

Page 6 of 13 of PTO 1449

Examiner's Initials	Doc No.	Journal name or type of document	Journal vol., no., page or Patent No.	Mo./Year	Author/Patentee	Class	Subclass	Filing date if appropriate
SW		Communications						
	180	Biochemical and Biophysical Research Communications	195, No. 2, 553-564	1993	Jesser et al.			
	181	Biochemical and Biophysical Research Communications	195(2), 553-64	1993	Jesser et al.			
	150	Biochemical and Biophysical Research Communications	210, No. 2, 329-337	1995	Aoki et al.			
	105	Biochemical and Biophysical Research Communications	220, 411-417	1996	Uchiyumi et al.			
	71	Biochemical and Biophysical Research Communications	235, 265-69	1997	Maruta et al.			
	555	Biochemical and Biophysical Research Communications	245, 1-10	1998	Rhun et al.			
	556	Biochemical and Biophysical Research Communications	278(3) Nov 30, 2000, 590-598	2000	Zhang et al.			
	291	Biochemical Society Transactions	Vol. 3 (2), 192-193	1980	Whitby et al.			
	188	Biochemical Society Transactions	21:330-334	1993	Beckman et al.			
	206	Biochemistry	30, 5907-5912	1991	Maruta et al.			
	240	Biochemistry International	16, No. 3, 397-403	1988	Concha et al.			
	229	Biochemistry International	19, No. 6, 1395-1402	1989	Tanuma et al.			
	230	Biochemistry International	18, No. 4, 701-708	1989	Tanuma et al.			
	200	Biochemistry International	24, No. 5, 369-697	1991	Tsar et al.			
	259	Biochimica et Biophysica Acta	827, 229-234	1985	Tavassoli et al.			
	189	Biochimica et Biophysica Acta	1158, 251-56	1993	Aoki et al.			
SW	142	Biochimie	Vol. 77 No. 5, pp. 408-22	1995	Griffin et al.			
Duplicate	107	Br. J. Pharm.	117:619-32	1996	Southan et al.			
Duplicate	103	Brain Res.	710: 169-77	1996	Wallis et al.			
Duplicate	120	Brain Res.	729:254-69	1996	Cosi et al.			
SW	551	Brain Research	809:53-67	1998	Cosi et al.			
SW	552	Brain	122:247-253	1999	Love et al.			
Duplicate	88	Brit. J. Pharm.	122:493-503	1997	Cuzzocrea			
SW	232	Bull. Chem. Soc. Jpn.	61(6):2238-40	1988	Sato et al.			
Duplicate	422	Bull. Soc. Chim. Fr.	233	1962	Granger et al.			
SW	366	C. R. Acad. Sci.	275:17, 961-64	1972	Michailidis et al.			
Duplicate	148	Can. J. Chem.	73, 319-35	1995	Desilets et al.			
SW	567	Can. J. Chem.	Vol 49, 2797-2802	1971	Horning			
	24	Cell	94, 325-337	1998	Kuida et al.			
	37	Cell	94, 339-352	1998	Hakem et al.			
	187	Cell Biology and Toxicology	9, No. 2, 165-175	1993	Clayson et al.			
	87	Cerebrovascular Disease	319-25	1997	Dawson et al.			
	441	Chem Abstracts	52:17 (14606h) (Sep 10)	1958	Ochiai et al.			
	428	Chem Abstracts	55:6 (5491ce) (Mar 20)	1961	Ochiai et al.			
	420	Chem Abstracts	58:4 (3425d) (Feb 13)	1963	Hayashi et al.			
	502	Chem Abstracts	vol. 126, No. 17, 229493f (4/28/97)	1997	Angeliki			
SW	397	Chem. Abstracts	64:695e	1966	Ried et al.			

Examiner: SW Date Considered: 5/22/02

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modeled after Form PTO 1449

542363

INFORMATION DISCLOSURE STATEMENT - FORM PTO 1449

Attorney Docket No. 2824

Serial No. 09/145,180

Applicant: LI et al.

Filing date: September 1, 1998

Group 1617

Page 7 of 13 of PTO 1449

Examiner's Initials	Doc. No.	Journal name or type of document	Journal vol., no., page or Patent No.	Mo./Year	Author/Patentee	Class	Subclass	Filing date if appropriate
SW	491	Chem. Ser.	46, pgs. 2087, 2089	1913	Kardos			
SW	494	Chemical Abstract	54:22648a	1955	Nikitskaya et al.			
Duplicate	443	Chemical Abstract	vol. 51:1960	1957	Taylor et al.			
SW	436	Chemical Abstract	vol. 52:5846a	1958	Schmidt-Nickels			
Duplicate	438	Chemical Abstract	vol. 52:6255	1958	Chia			
SW	440	Chemical Abstract	vol. 52:4646	1958	Giiman et al.			
Duplicate	483	Chemical Abstract	vol. 52:5846b	1958	Gateff et al.			
SW	430	Chemical Abstract	vol. 54:22647	1960	Campbell			
	427	Chemical Abstract	vol. 55:12868a	1961				
	481	Chemical Abstract	vol. 55:12868b	1961				
	482	Chemical Abstract	vol. 55:12868c	1961				
	418	Chemical Abstract	vol. 58:7884	1963	Sieglitz			
	419	Chemical Abstract	vol. 59:10037b	1963	Dokunikhin et al.			
SW	493	Chemical Abstract	vol. 59:10037c	1963	Hazard et al.			
Duplicate	410	Chemical Abstract	vol. 61:15194	1964	Tsupoi			
SW	412	Chemical Abstract	vol. 61:13305h	1964	Cuelet			
	414	Chemical Abstract	vol. 61:9493g	1964	Dokunikhin et al.			
	479	Chemical Abstract	vol. 61:9494a	1964	Dokunikhin et al.			
	480	Chemical Abstract	vol. 61:9493f	1964	Bodea et al.			
	492	Chemical Abstract	vol. 61:13305g	1964	Badger et al.			
SW	405	Chemical Abstract	vol. 63:7006	1965	Pernin			
Duplicate	406	Chemical Abstract	vol. 62:5259	1965	Lakeside Lab., Inc.			
SW	407	Chemical Abstract	vol. 62:9129e	1965	Kuehn			
Duplicate	408	Chemical Abstract	vol. 63:4256	1965	Keene et al.			
SW	478	Chemical Abstract	vol. 62:9129g	1965	Klosa			
SW	399	Chemical Abstract	vol. 65:15320a	1966	Kametani			
SW	401	Chemical Abstract	vol. 64:3526h	1966	Crossland			
SW	484	Chemical Abstract	vol. 65:15319h	1966	Humber et al.			
SW	389	Chemical Abstract	vol. 69:87767	1968	Hofer			
Duplicate	391	Chemical Abstract	vol. 68:59420	1968	Chandler et al.			
Duplicate	383	Chemical Abstract	vol. 70:3629	1969	Weis			
Duplicate	384	Chemical Abstract	vol. 70:67988	1969	Resplandy et al.			
SW	386	Chemical Abstract	vol. 70:115926	1969	Hofer			
Duplicate	387	Chemical Abstract	vol. 70:4079	1969	Coyne et al.			
Duplicate	376	Chemical Abstract	vol. 73:35200	1970	Pan et al.			
Duplicate	377	Chemical Abstract	vol. 72:121337	1970	Pan et al.			
SW	371	Chemical Abstract	vol. 74:111797	1971	Mavoungou-Gomes			
	374	Chemical Abstract	vol. 75:98422	1971	Campbell			
	496	Chemical Abstract	74:110112y (pg 252 May 10)	1971	Damas			
	360	Chemical Abstract	vol. 77:61927	1972	Zinchenko			
	363	Chemical Abstract	vol. 76:14566	1972	Rodway			
SW	367	Chemical Abstract	vol. 76:85774	1972	Mavoungou-			

Examiner: SW Date Considered: 5/22/02

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modeled after Form PTO 1449

## Attorney Docket No. 2824

Serial No. 09/145,180

Applicant: LI et al.

Filing date: September 1, 1998

Group 1617

Page 8 of 13 of PTO 1449

Examiner: S. V. 30 <sup>8</sup> Date Considered: 5/22/02

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modeled after Form PTO 1449

542363

## INFORMATION DISCLOSURE STATEMENT - FORM PTO 1449

Attorney Docket No. 2824

Serial No. 09/145,180

Applicant: LI et al.

Filing date: September 1, 1998

Group 1617

Page 9 of 13 of PTO 1449

Examiner's initials	Doc. No.	Journal name or type of document	Journal vol., no., page or Patent No.	Mo., Year	Author/Patentee	Class	Subclass	Filing date if appropriate
	Duplicate	282 Chemical Abstract	vol. 97:126680	1982	Grimsnaw et al.			
	Duplicate	264 Chemical Abstract	vol. 100:103453	1984	Prostakov et al.			
	Duplicate	265 Chemical Abstract	vol. 100:191713	1984	Crlic-Nuber et al.			
<i>SW</i>		266 Chemical Abstract	vol. 100:139054	1984	Oleinik			
	Duplicate	260 Chemical Abstract	vol. 102:203854	1985	Migachev et al.			
	Duplicate	258 Chemical Abstract	vol. 105:60305	1986	Anchevskii et al.			
<i>SW</i>		243 Chemical Abstract	vol. 106:67553	1987	Peilefier			
<i>SW</i>		248 Chemical Abstract	vol. 107:23262	1987	Capares			
<i>SW</i>		249 Chemical Abstract	vol. 107:39635v	1987	Bondarenko et al.			
<i>SW</i>		238 Chemical Abstract	vol. 108:21627	1988	Duval			
	Duplicate	228 Chemical Abstract	vol. 110:230971	1989	Vai'kova et al.			
	Duplicate	216 Chemical Abstract	vol. 113:190649	1990	Vai'kova et al.			
	Duplicate	223 Chemical Abstract	vol. 112:44716	1990	Korol'kova et al.			
	Duplicate	224 Chemical Abstract	vol. 112:128235	1990	Korol'kova et al.			
	Duplicate	226 Chemical Abstract	vol. 112:216749	1990	Benson et al.			
	Duplicate	199 Chemical Abstract	vol. 114:143456	1991	Waiser			
<i>SW</i>		205 Chemical Abstract	vol. 115:232107	1991	Nagao			
<i>SW</i>		209 Chemical Abstract	vol. 115:70731f	1991	Donsnikh et al.			
<i>SW</i>		212 Chemical Abstract	vol. 115:158338	1991	Buckman et al.			
	Duplicate	213 Chemical Abstract	vol. 114:42543	1991	Anchevskii et al.			
	Duplicate	169 Chemical Abstract	vol. 119:72127	1993	Zaitsev et al.			
	Duplicate	182 Chemical Abstract	vol. 118:191567	1993	Cow			
	Duplicate	184 Chemical Abstract	vol. 118:90722	1993	Dininno et al.			
	Duplicate	185 Chemical Abstract	vol. 118:101709	1993	Dininno et al.			
	Duplicate	156 Chemical Abstract	vol. 120:134231	1994	Rocca et al.			
<i>SW</i>		158 Chemical Abstract	vol. 121:220651v	1994	Pawlowska et al.			
	Duplicate	159 Chemical Abstract	vol. 121:172572	1994	Liu et al.			
<i>SW</i>		161 Chemical Abstract	vol. 120:95793	1994	Kyota et al.			
	Duplicate	166 Chemical Abstract	vol. 121:57315	1994	Dow et al.			
<i>SW</i>		167 Chemical Abstract	vol. 120:148508p	1994	Barros et al.			
	Duplicate	126 Chemical Abstract	vol. 123:505	1995	Weitin et al.			
	Duplicate	134 Chemical Abstract	vol. 122:10865	1995	Lampa et al.			
	Duplicate	137 Chemical Abstract	vol. 122:170499	1995	Korol'kova et al.			
<i>SW</i>		138 Chemical Abstract	vol. 123:256711	1995	Kalindjian et al.			
	Duplicate	144 Chemical Abstract	vol. 122:170250	1995	Gorio et al.			
	Duplicate	147 Chemical Abstract	vol. 122:187249	1995	Dininno et al.			
<i>SW</i>		486 Chemical Abstract	122:316902	1995	Desilets et al.			
<i>SW</i>		487 Chemical Abstract	122:316901	1995	Desilets et al.			
<i>SW</i>		488 Chemical Abstract	122:187526	1995	Langlois et al.			
<i>SW</i>		100 Chemical Abstract	vol. 125:37882	1996	Yamaguchi et al.			
	Duplicate	108 Chemical Abstract	vol. 124:331706	1996	Silverman et al.			
<i>SW</i>		110 Chemical Abstract	vol. 124:131261	1996	Richter			
<i>SW</i>		113 Chemical Abstract	vol. 126:115554	1996	Malhotra et al.			
	Duplicate	116 Chemical Abstract	vol. 125:246943	1996	Korol'kova et al.			

Examiner: *S. V. W.* <sup>9</sup> Date Considered: *5/22/02*

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modeled after Form PTO 1449

542363



INFORMATION DISCLOSURE STATEMENT - FORM PTO 1449

Attorney Docket No. 2824

Serial No. 09/145,180

Applicant: LI et al.

Filing date: September 1, 1998

Group 1617

Page 10 of 13 of PTO 1449

Examiner's Initials	Doc No.	Journal name or type of document	Journal vol., no., page or Patent No.	Mo./Year	Author/Patentee	Class	Subclass	Filing date if appropriate
SW	117	Chemical Abstract	vol. 125:277-462	1996	Ge et al.			
SW	485	Chemical Abstract	124:2020-47	1996	Fernandez et al.			
SW	67	Chemical Abstract	vol. 129:36109	1997	Sakai et al.			
Duplicate	69	Chemical Abstract	vol. 127:234258	1997	Reddy et al.			
SW	72	Chemical Abstract	vol. 127:81282	1997	Marek et al.			
Duplicate	79	Chemical Abstract	vol. 128:34782	1997	Jones et al.			
SW	93	Chemical Abstract	vol. 127:30243	1997	Banister et al.			
SW	8	Chemical Abstract	abstract no. 17462	1998	Yoshida et al.			
Duplicate	10	Chemical Abstract	vol. 129:104224	1998	West			
Duplicate	11	Chemical Abstract	vol. 128:138099	1998	Weltin et al.			
Duplicate	15	Chemical Abstract	vol. 130:24816	1998	Park et al.			
Duplicate	25	Chemical Abstract	vol. 128:75320	1998	Jones et al.			
Duplicate	41	Chemical Abstract	vol. 128:165850	1998	Cookson et al.			
Duplicate	43	Chemical Abstract	vol. 129:54301	1998	Albright et al.			
Duplicate	44	Chemical Abstract	No. 816103	1998	Albright et al.			
SW	435	Chemical Abstracts	vol. 52 (21) 18420c	1958	Tanida			
Duplicate	409	Chemical Abstracts	vol. 62, no. 5, 5271c Mar.	1965				
SW	364	Chemical Abstracts	vol. 76 (25) 153704b	1972	Poznarskii et al.			
SW	307	Chemical Abstracts	vol. 88 (7) 49887	1978	Szacowski			
Duplicate	314	Chemical Abstracts	88, No. 13, 505 (88:89502c)	1978	Dokunikhin et al.			
Duplicate	289	Chemical Abstracts	94, No. 23, 637(192098y)	1981	Migachev			
SW	45	Chemical Abstracts	Registry No. 17 1399-15-3	1998				
SW	46	Chemical Abstracts	Registry No. 14223 8-47-9	1998				
	344	Chemical Abstracts 85:159898a	85, No. 21, 531	1974	Upadysneva et al.			
	562	Chem. Lett.	39-42	1990	Chiba et al.			
	312	Chemical and Pharmaceutical Bulletin	vol. 26, no. 12, pp. 3682-94	1978	Hamada et al.			
	385	Chemische Berichte	vol. 102, 1161-1176	1969	Kaufmann et al.			
SW	61	Eur. J. Biochem.	Vol. 244, pp. 15-20	1997	Van Gool et al.			
Duplicate	160	Eur. J. Med Chem.	29, 925-40	1994	Langlois et al.			
SW	204	Eur. J. Pharm.	204, 339-40	1991	Nowicki et al.			
	423	Gazz. Chim. Ital.	91:1345-51	1962	Di Maio et al.			
	424	Gazz. Chim. Ital.	91:1124-32	1962	Di Maio et al.			
	415	Gazz. Chim. Ital.	94:5, 590-94	1964	Di Maio et al.			
	546	Hawleys Chemical Condense Dictionary	Sax (Ed) 11th Ed, 1987 p898	1987	Hawley's			
	268	Heterocycles	22:2, 237-40	1984	Naito et al.			
	127	Int. J. Immunopharmac	17, No. 4, 265-271	1995	Weltin et al.			
	59	Int. J. Radiat. Biol.	Vol. 72 No. 6, pp. 685-692	1997	Weltin et al.			
SW	261	Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med.	Vol. 48 No. 5, pp. 675-690	1985	Harris			
Duplicate	122	Intl. J. Oncol	8:239-52	1996	Bauer et al.			
SW	538	IPER for PCT/US98/18189						
SW	157	IS&T's Tenth Int'l Congress on	246-248	1994	Richter et al.			

Examiner: SW 10 Date Considered: 5/20/02

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modeled after Form PTO 1449

542363

INFORMATION DISCLOSURE STATEMENT - FORM PTO 1449

Attorney Docket No. 2824

Serial No. 09/145,180

Applicant: LI et al.

Filing date: September 1, 1998

Group 1617

Page 11 of 13 of PTO 1449

Examiner's Initials	Doc. No.	Journal name or type of document	Journal vol., no., page or Patent No.	Mo./Year	Author/Patentee	Class	Succlass	Filing date if appropriate
SV		Advances in Non-Impact Printing Technologies						
	541	ISR for PCT/US98/18185	PCT/US98/18185	1998				
	539	ISR for PCT/US98/18186	PCT/US98/18186	1999				
	535	ISR for PCT/US98/18187	PCT/US98/18187	1997				
	538	ISR for PCT/US98/18188	PCT/US98/18188	1997				
	537	ISR for PCT/US98/18189	PCT/US98/18189	1997				
	543	ISR for PCT/US98/18195	PCT/US98/18195	1997				
	540	ISR for PCT/US98/18196	PCT/US98/18196	1998				
	542	ISR for PCT/US98/18226	PCT/US98/18226	1997				
	544	ISR for PCT/US99/30971	PCT/US99/30971	1998				
	547	ISR for PCT/US99/30979	PCT/US99/30979	1998				
SV	369	Itsu Kenkusho Nempo	16:15-23	1971	Ochiai et al.			
Duplicate	85	J. Cerebral Flood Flow Metabol.	17(11): 1143-51	1997	Encres et al.			
SV	315	J. Chem. Soc.	11:1293-97	1978	Davies et al.			
SV	447	J. Am. Chem. Soc.	78:5104-8	1956	Taylor et al.			
Duplicate	140	J. Biol. Chem.	270:19, 11176-80	1995	Heiler et al.			
SV	365	J. Biol. Chem.	246(20), 6362-64	1972	Miwa et al.			
	254	J. Biol. Chem.	261(32), 14902-11	1986	Hatakeyama et al.			
	244	J. Biol. Chem.	262(36), 17641-50	1987	Ikejima et al.			
	237	J. Biol. Chem.	263(23), 11037-40	1988	Ikejima et al.			
SV	190	J. Biol. Chem.	267(20), 14436-42	1992	Tsai et al.			
Duplicate	194	J. Biol. Chem.	267:3, 1569-75	1992	Banasik et al.			
Duplicate	65	J. Biol. Chem.	272:9030-36	1997	Szabo et al.			
SV	375	J. Chem. Soc.	12:2231-2241	1971	Barton			
	132	J. Chem. Res., Synop.	8:302	1995	Mueller et al.			
	111	J. Chem. Res., Synop.	2:126	1996	Mueller et al.			
	463	J. Chem. Soc.	pp. 1979-1984	1929	Blount et al.			
	439	J. Chem. Soc.	1624-28	1958	Jonsson			
	425	J. Chem. Soc.	4295-98	1962	Brown et al.			
	345	J. Chem. Soc.	1:14, 1747-51	1974	Ninomiya et al.			
	349	J. Chem. Soc.	1:7, 763-70	1974	Bailey et al.			
	561	J. Chem. Soc.	812	1956	McConnell et al.			
	503	J. Exp. Med.	Vol 186, No. 7, 1041-9	1997	Szabo			
SV	378	J. Het. Chem.	vol. 7, pp. 597-605	1970	Pan et al.			
	274	J. Heterocycl. Chem.	20:5, 1407-9	1983	Rougeot et al.			
Duplicate	162	J. Immuno.	153:3319-25	1994	Hugnes et al.			
SV	128	J. Med. Chem.	38:389-393	1995	Siama et al.			
	129	J. Med. Chem.	38, 4332-4336	1995	Siama et al.			
	563	J. Med. Pharm. Chem.	3: 1961; 157, 159	1961	Gootjes et al.			
	123	J. Neurochem.	65:3, 1411-14	1995	Zhang et al.			
	186	J. Neurosci.	13:6, 2651-61	1993	Dawson et al.			
SV	118	J. Neurosci.	16:8, 2479-87	1996	Dawson et al.			

Examiner: SV 11 Date Considered: 5/22/02

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modeled after Form PTO 1449

542363

## INFORMATION DISCLOSURE STATEMENT - FORM PTO 1449

Attorney Docket No. 2824-

Serial No. 09/145,180

Applicant: LI et al.

Filing date: September 1, 1998

Group 1617

Page 12 of 13 of PTO 1449

Examiner's Initials	Doc. No.	Journal name or type of document	Journal vol., no., page or Patent No.	Mo./Year	Author/Patentee	Class	Subclass	Filing date if appropriate
SW	498	J. Neuroscience Res.	47: 372-383	1997	Ceruti et al.			
	250	J. of Biological Chemistry	251(2), 965-69	1986	Tanuma et al.			
	413	J. Org Chem	29:3, 581-85	1964	Masamune et al.			
	475	J. Org Chem.	47: 2043-2047	1982	Tayicr et al.			
	437	J. Org. Chem.	vol. 23, pp. 1071-2 July	1958	Robinson et al.			
	417	J. Org. Chem.	23:11, 3160-85	1954	Baer et al.			
	313	J. Org. Chem.	43:11, 2190-96	1978	Eisch et al.			
	564	J. Phys. Org. Chem	10: 7, 1997; 499-513	1997	Arnett et al.			
	174	J. Urol.	Vol. 150, pp. 1526-1532	1993	Sklar et al.			
	458	JACS	71:937-8 (Mar)	1949	Wilson et al.			
SW	451	JACS	76:4396-8 (Sep 5)	1954	Wright			
Duplicate	64	Japanese J. Pharm.	75, Supp. I:102	1997	Szaco et al.			
Duplicate	66	Japanese J. Pharm.	75, Supp. I:15	1997	Saizman et al.			
SW	456	JCS	pp. 4067-75	1952	Peak et al.			
	448	JCS	pp.1294-304	1956	Albert et al.			
	433	JCS	pp. 2384-96	1959	Albert et al.			
	262	Journal of Cellular Biochemistry	29:361-372	1985	Boiander, Jr.			
SW	63	Journal of Cerebral Blood Flow and Metabolism	17 No. 11, 1137-1142	1997	Takanashi et al.			
Duplicate	402	Journal of Heterocyclic Chemistry	vol. 3, pp. 466-9 Dec.	1966	Aparajithan			
SW	308	Journal of Heterocyclic Chemistry	vol. 15, pp. 1513-4	1978	Nuvole et al.			
	321	Journal of Medicinal Chemistry	vol. 20 (3) 449-452	1977	Diana et al.			
	568	Journal of Medicinal Chemistry	35(5)823-832	1992	Ccain			
	42	Journal of Neurochemistry	70, No. 2, 501-508	1998	Cookson et al.			
	460	Journal of Organic Chemistry	vol. 11, no. 3, 239-246	1946	Bergstrom et al.			
	239	Journal of Organic Chemistry	53(20):4650-3	1988	D. Dumas			
	362	Journal of the Chemical Society	pp. 1799-1803	1972	Singh et al.			
	330	Journal of the Chemical Society	vol. 9, 944-950	1976	Loewenthal et al.			
	490	Justus Liebig's Ann. Chem.	388, p. 212	1912	Ullmann et al.			
	121	Med Chem. Res.	6.2, 31-101	1996	Castan et al.			
	168	Molec. Cell. Biochem.	138:185-97	1994	Banasik et al.			
	231	Mutation Research	218, 67-74	1989	Gonzalez et al.			
	104	Mutation Research	350, 25-34	1996	Wachsman			
	86	Nature Medicine	JHU	1997	Eliasson et al.			
	242	Neuron	1, 623-634	1988	Choi			
	170	NeuroReport	5.3, 245-48	1993	Wallis et al.			
SW	557	Nucleic Acids Research	29(3) 841-849	2001	Simoulan-Rosenthal et al			
Duplicate	155	Oncol. Res.	6:9, 399-403	1994	Wetlin et al.			
Duplicate	73	Pain	Vol. 72, pp. 355-366	1997	Mao et al.			
SW	444	Pharm. Bull.	5.289-91	1957	Ochiai et al.			
SW	275	Phosphorus Sulfur	vol. 14, no. 1, pp. 131-8	1983	Becrer et al.			
SW	210	Proc. Natl. Acad. Sci. USA	88:6368-71	1991	Dawson et al.			
Duplicate	106	Proc. Natl. Acad. Sci. USA	93:1753-58	1996	Szaco et al.			
SW	62	Proc. Natl. Acad. Sci. USA	94:679-83	1997	Thiemermann et			

Examiner: SW 12 Date Considered: 5/22/02

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modeled after Form PTO 1449

542363

INFORMATION DISCLOSURE STATEMENT - FORM PTO 1449

Attorney Docket No. 2824

Serial No. 09/145,180

Applicant: LI et al.

Filing date: September 1, 1998

Group 1617

Page 13 of 13 of PTO 1449

Examiner's Initials	Doc No.	Journal name or type of document	Journal vol., no., page or Patent No.	Mo./Year	Author/Patentee	Class	Succlass	Filing date if appropriate
SW					al.			
	Duplicate	109 Proc. Natl. Acad. Sci. USA	[Vol. 93, pp. 7481-7485	1996	Rui et al.			
SW		553 Proc. Natl. Acad. Sci. USA	[96:5774-5779 (May)	1999	Mandie et al.			
		234 Radiat. Res.	[Vol. 116 No. 3, pp. 442-452	1988	Paapnorst et al.			
		554 Radiat. Res.	[101:29-46	1985	Olenik			
		75 Res. Comm. Mol. Pathol. Pharmacol.	[Vol. 95 No. 3, pp. 241-252	1997	Lam			
		390 Ric. Sci.	[38:3, 231-33	1968	Di Maio et al.			
		392 Roc. Chem.	[41:1, 89-101	1967	Schoen et al.			
		269 Science	[223:589-91	1984	Milam et al.			
		153 Science	[263:687-89	1994	Zhang et al.			
		164 Science	[255:1883-1885	1994	Huang et al.			
SW		12 Science	[282, 1484-1487	1998	Smith et al.			
	Duplicate	98 Shock	[5(4):258-64	1996	Zingarelli et al.			
SW		370 Spin Label Analogue of ATP	[246, No. 20, 6362-6364	1971	Miwa et al.			
SW		316 Switzerland Patent	[601 246	1978				
	Duplicate	119 Terato., Carcino., and Muta.	[16:219-27	1996	Cristovao et al.			
SW		396 Tetrahedron	[supp. 8, part 1, pp. 305-12	1966	Tamayo et al.			
SW		211 Tetrahedron Letters	[32, No. 35, 4525-4528	1991	Chida et al.			
SW		125 Tetrahedron Letters	[36:33, 5983-86	1995	White et al.			
SW		101 Tetrahedron Letters	[52:9, 3117-34	1996	White et al.			
	Duplicate	60 The EMBO Journal	[Vol. 16 No. 19, pp. 6018-6033	1997	Vaziri et al.			
SW		395 The Journal of Biological Chemistry	[242, No. 22, 5301-5307	1967	Futai et al.			
		276 The Journal of Biological Chemistry	[Vol. 257, No. 21, 12872-12877	1982	Wieckens et al.			
		267 The Journal of Biological Chemistry	[259, No. 2, 986-995	1984	Oka et al.			
		252 The Journal of Biological Chemistry	[261, No. 2, pp. 965-969	1986	Tanuma et al.			
		236 The Journal of Biological Chemistry	[263, No. 23, 11037-11040	1988	Ikejima et al.			
		74 The Journal of Biological Chemistry	[272, No. 18, 11895-11901	1997	Lin et al.			
		222 TIPS	[11, 379-387	1990	Meldrum et al.			
		14 TIPS	[in press	1998	Pieper et al.			
		81 Trends Neurosci.	[20:3, 132-139	1997	Iadecola			
SW		58 Vertex Pharmaceuticals Inc.	[PR Newswire	1998				

Examiner: S. W. R. 13 Date Considered: 5/22/02

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modeled after Form PTO 1449

542363